US 12,290,565 B2
Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers
Shih-Yao Lin, Taipei (TW); Feng-Lin Chiang, Taipei (TW); and You-Chia Yeh, Taipei (TW)
Assigned to AltruBio Inc., Wilmington, DE (US)
Filed by AltruBio Inc., Wilmington, DE (US)
Filed on Nov. 16, 2022, as Appl. No. 18/056,166.
Claims priority of provisional application 63/280,463, filed on Nov. 17, 2021.
Prior Publication US 2023/0149544 A1, May 18, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 31/519 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 31/519 (2013.01); A61P 37/06 (2018.01); C07K 16/2896 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/92 (2013.01)] 23 Claims
 
1. A method of treating a T-cell mediated inflammatory disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that specifically binds to human PSGL-1 in combination with a Janus kinase (JAK) inhibitor; wherein the antibody that specifically binds to human PSGL-1 comprises a heavy chain comprising a heavy chain variable (VH) domain and a light chain comprising a light chain variable (VL) domain, wherein the VH domain comprises a CDR-H1 comprising the amino acid sequence SFGMH (SEQ ID NO:8), a CDR-H2 comprising the amino acid sequence YINGGSSTIFYANAVKG (SEQ ID NO:9), and a CDR-H3 comprising the amino acid sequence YASYGGGAMDY (SEQ ID NO:10), and wherein the VL domain comprises a CDR-L1 comprising the amino acid sequence RSSQSIVHNDGNTYFE (SEQ ID NO: 5), a CDR-L2 comprising the amino acid sequence KVSNRFS (SEQ ID NO:6), and a CDR-L3 comprising the amino acid sequence FQGSYVPLT (SEQ ID NO:7).